Zhao et al. recently reported the enhanced expression of CD107a molecules during intratumoral IL-12 gene therapy that cross prime CD8+ Tc1 cells reactive against tumor associated stromal antigens [48]. The gene discussed is CD8A; the disease is neoplasm.